Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Hoberück

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Nuklearmedizin. Nuclear Medicine|August 24, 2019
68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patientsSebastian Hoberück, Enrico Michler, Gerd Wunderlich, et al.
Clinical Imaging|October 30, 2020
Adrenal glands enhancement in computed tomography as predictor of short-and intermediate term mortality in critically ill patientsRobert Winzer, Ron Martin, Jens-Peter Kühn, et al.
BJU International|July 2, 2026
Ablative radiotherapy in castration-resistant prostate cancerTobias Hölscher, Fabian Lohaus, Lydia Koi, et al.
EJNMMI Research|October 19, 2021
Intraindividual comparison of [<sup>68</sup> Ga]-Ga-PSMA-11 and [<sup>18</sup>F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysisSebastian Hoberück, Steffen Löck, Angelika Borkowetz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2021
PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-TrivehexinNeil Gerard Quigley, Katja Steiger, Sebastian Hoberück, et al.
BJU International|August 23, 2025
Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CTMatthias Miederer, Marc Pretze, Elena Abbate, et al.
Abdominal Radiology (New York)|August 17, 2021
Diagnostic performance of <sup>18</sup>F-fluorodeoxyglucose-PET/MRI versus MRI alone in the diagnosis of pelvic recurrence of rectal cancerVerena Plodeck, Ivan Platzek, Johannes Streitzig, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 11, 2025
[<sup>68</sup>Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based ChemotherapyStephan Beintner-Skawran, Andrei Gafita, Theo Lorenzini, et al.
Journal of Medicinal Chemistry|October 13, 2025
"Precision on Two Wheels"─Structural Refinement of <sup>64</sup>Cu- and <sup>68</sup>Ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved Tumor Imaging: From Preclinical Development to First-in-Human ApplicationTobias Krönke, Johanna Trommer, Martin Ullrich, et al.
The Lancet. Oncology|August 1, 2024
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective studyMadeleine J Karpinski, Johannes Hüsing, Kevin Claassen, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Nuklearmedizin. Nuclear Medicine|August 24, 2019
68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patientsSebastian Hoberück, Enrico Michler, Gerd Wunderlich, et al.
Clinical Imaging|October 30, 2020
Adrenal glands enhancement in computed tomography as predictor of short-and intermediate term mortality in critically ill patientsRobert Winzer, Ron Martin, Jens-Peter Kühn, et al.
BJU International|July 2, 2026
Ablative radiotherapy in castration-resistant prostate cancerTobias Hölscher, Fabian Lohaus, Lydia Koi, et al.
EJNMMI Research|October 19, 2021
Intraindividual comparison of [<sup>68</sup> Ga]-Ga-PSMA-11 and [<sup>18</sup>F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysisSebastian Hoberück, Steffen Löck, Angelika Borkowetz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2021
PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-TrivehexinNeil Gerard Quigley, Katja Steiger, Sebastian Hoberück, et al.
BJU International|August 23, 2025
Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CTMatthias Miederer, Marc Pretze, Elena Abbate, et al.
Abdominal Radiology (New York)|August 17, 2021
Diagnostic performance of <sup>18</sup>F-fluorodeoxyglucose-PET/MRI versus MRI alone in the diagnosis of pelvic recurrence of rectal cancerVerena Plodeck, Ivan Platzek, Johannes Streitzig, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 11, 2025
[<sup>68</sup>Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based ChemotherapyStephan Beintner-Skawran, Andrei Gafita, Theo Lorenzini, et al.
Journal of Medicinal Chemistry|October 13, 2025
"Precision on Two Wheels"─Structural Refinement of <sup>64</sup>Cu- and <sup>68</sup>Ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved Tumor Imaging: From Preclinical Development to First-in-Human ApplicationTobias Krönke, Johanna Trommer, Martin Ullrich, et al.
The Lancet. Oncology|August 1, 2024
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective studyMadeleine J Karpinski, Johannes Hüsing, Kevin Claassen, et al.
Pageof 4